ARKG
ARK GENOMIC REVOLUTION ETF
FUND DETAILSWHY INVEST IN ARKG?
Exposure to Innovation: Aims for thematic multi-cap exposure to innovative
elements including gene therapy bio-informatics, bio-inspired computing,molecular medicine, and pharmaceutical innovations.
Growth Potential: Aims to capture long-term growth with low correlation ofrelative returns to traditional growth strategies and negative correlation to value
strategies.
Tool for Diversification: Offers a tool for diversification due to little overlap withtraditional indices. It can be a complement to traditional value/growth strategies.

Ticker

ARKG

TypeActive Equity ETF

CUSIP

Cost Effective: Provides a lower cost alternative to mutual funds with true active
management in an Exchange Traded Fund (ETF) that invests in rapidly moving
themes.

US00214Q3020

Primary Exchange

Cboe BZX

Inception Date

2014-10-31

Expense Ratio

SPX Index

0.75%

Fund AUM$1.28 Billion
ARK Investment Management LLC

Fund Distributor

Foreside Fund Services, LLC

Number of Holdings

40-60

Weighted Avg. Market Cap.

12 Billion

Median Market Cap.

1 Billion

Active Share (S&P500)

99%

FUND OBJECTIVEGROWTH OF 10,000 USD SINCE INCEPTION
NAV00214Q302

ISINAdvisor

Grounded in Research: Combines top-down and bottom-up research in its
portfolio management to identify innovative companies and convergence acrossmarkets.

As of June 30, 2024

M1WO Index

ARKG is an actively managed ETF that seeks long-term growthof capital by investing under normal circumstances primarily(at least 80% of its assets) in domestic and foreign equity
securities of companies across multiple sectors, including
health care, information technology, materials, energy andconsumer discretionary, that are relevant to the Fund's
investment theme of the genomics revolution. Companies
within ARKG are focused on extending and enhancing thequality of human and other life by incorporating technologicaland scientific developments and advancements in genomics
into their business.

XNBI Index

$60k
$50k
$40k
$30k
$20k
$10k
Jan Jul
Ja
Ju
Ja
Ju
Ja
Ju
Ja
Ju
Ja
Ju
Ja
Ju
Ja
JuJa
Ju-15 -15 n-16 l-16 n-17 l-17 n-18 l-18 n-19 l-19 n-20 l-20 n-21 l-21 n-22 l-22 n-23 l-23

TOP 10 HOLDINGSThe line graph represents the cumulative performance of a hypothetical $10,000 investment. The returns are
net of the ETF's expenses but do not reflect the payment of any brokerage commissions or brokerage costs
incurred as a result of buying or selling fund shares and do not reflect the deduction of taxes to which aninvestor would be subject as a result of owning or selling shares of the fund. If they did, the returns would belower than those shown.

FUND PERFORMANCE
1 MonthFor periods ended June 30, 2024
3 Months

YTD

1 Year

3 Years

5 Years

Since
Inception

ARKG | NAV-4.07%-18.19%-28.21%-30.99%-36.51%-6.52%

2.53%

ARKG | Market Price-4.16%-18.36%-28.44%-31.12%-36.55%-6.56%

2.50%

3.37%

2.85%

4.47%

12.43%-3.28%

6.59%

4.64%

NASDAQ Biotech. Index [XNBI]S&P 500 Index [SPX]

3.59%

4.28%

15.29%

24.56%

10.01%

15.05%

13.03%MSCI World Index [M1WO]

2.03%

2.63%

11.75%

20.19%

6.86%

11.78%

9.78%

Past performance does not guarantee future results. The performance data quoted represents past performance andcurrent returns may be lower or higher. The investment return and principal will fluctuate so that an investor's shares
when redeemed may be worth more or less than the original cost. For the Fund's most recent month end performance,

please visit www.ark-funds.com or call 1-800-679-7759. Returns for less than one year are not annualized. Net
asset value ("NAV") returns are based on the dollar value of a single share of the ETF, calculated using the valueof the underlying assets of the ETF minus its liabilities, divided by the number of shares outstanding. The NAV istypically calculated at 4:00 pm Eastern time on each business day the Cboe BZX Exchange is open for trading.
Market returns are based on the trade price at which shares are bought and sold on the Cboe BZX Exchange,
Inc. using the last share trade. Market performance does not represent the returns you would receive if youtraded shares at other times. Total Return reflects reinvestment of distributions on ex-date for NAV returns andpayment date for Market Price returns. The market price of the ETF's shares may differ significantly from their
NAV during periods of market volatility.

SECURITY NAME

As of June 30, 2024

WEIGHT

1Twist Bioscience Corp

2

CRISPR Therapeutics AG

7.4%

3CareDx Inc

6.9%

4Recursion Pharmaceuticals Inc

5.6%

5Ionis Pharmaceuticals Inc

5.0%

6Intellia Therapeutics Inc

4.5%

7

Beam Therapeutics Inc

3.8%

8

Nurix Therapeutics Inc

3.8%

9

Arcturus Therapeutics Holdings Inc

3.7%

10

Schrodinger Inc/United States

3.7%

10.1%

54.5%
Holdings are subject to change.
For current portfolio holdings
please download "Fund Holdings" as a CSV or PDF at ark-funds.com.
Portfolio holdings should not be considered as investment advice ora recommendation to buy, sell or hold any particular security. Thesecurities identified do not represent all of the securities purchased, soldor recommended for client accounts. It should not be assumed that aninvestment in the securities identified was or will be profitable.

Financial Professionals and Institutional Investors should contact our sales partner, Resolute Investment Distributors: 1-800-679-7759 | etfs@ark-invest.com | ark-funds.com

ARKG

ARK GENOMIC REVOLUTION ETF

Information as of June 30, 2024MARKET CAPITALIZATIONTECHNOLOGY BREAKDOWN
Precision Therapies

43.5%

Mega ($100B+)

5.9%

Multiomic Technologies

27.4%

Large ($10 - $100B)

8.8%

Programmable Biology

12.9%

Medium ($2 - $10B)

40.2%

Neural Networks

5.6%

Small ($300M - $2B)

38.7%

Next Gen Cloud

3.1%

Micro ($50 - $300M)

6.1%

Adaptive Robotics

1.5%Intelligent Devices

1.0%

SECTOR BREAKDOWN
Health Care

96.8%

Information Technology

2.3%

Materials

0.5%

GEOGRAPHIC BREAKDOWN
North America

91.6%

Western Europe

8.4%

Holdings are subject to change. The Technology Breakdown is based on ARK's internal thematic research elements and portfolio company classification. Geographic Breakdown relates
principally to the domicile of the issuers of the securities held in the ETF. Sector Breakdown is based on the Global Industry Classification Standard (GICS).

Before investing you should carefully consider the Fund's investment objectives, risks, charges and expenses. This and other information is in
the prospectus, a copy of which may be obtained by visiting www.ark-funds.com. Please read the prospectus carefully before you invest.
The principal risks of investing in ARKG: Equity Securities Risk. The value of the equity securities the Fund holds may fall due to general market and economic conditions. Foreign Securities Risk.
Investments in the securities of foreign issuers involve risks beyond those associated with investments in U.S. securities. Health Care Sector Risk. The health care sector may be adversely affectedby government regulations and government health care programs, restrictions on government reimbursements for medical expenses, increases or decreases in the cost of medical products
and services and product liability claims, among other factors. Many health care companies are heavily dependent on patent protection and intellectual property rights and the expiration ofa patent may adversely affect their profitability. Biotechnology Company Risk. A biotechnology company's valuation can often be based largely on the potential or actual performance of alimited number of products and can accordingly be greatly affected if one of its products proves, among other things, unsafe, ineffective or unprofitable. Biotechnology companies are subject
to regulation by, and the restrictions of, the U.S. Food and Drug Administration, the U.S. Environmental Protection Agency, state and local governments, and foreign regulatory authorities.
Pharmaceutical Company Risk. Companies in the pharmaceutical industry can be significantly affected by, among other things, government approval of products and services, government
regulation and reimbursement rates, product liability claims, patent expirations and protection and intense competition. Detailed information regarding the specific risks of ARKG can befound in the ETF's prospectus. Additional risks of investing in ARKG include Foreign Securities Risk, Information Technology Sector Risk, equity, market, management and non-diversification
risks, as well as fluctuations in market value and NAV. An investment in an ETF is subject to risks and you can lose money on your investment in an ETF. There can be no assurance that the ETF
will achieve its investment objective. The ETF's portfolio is more volatile than broad market averages. Shares of ARKG are bought and sold at market price (not NAV) and are not individuallyredeemed from the ETF. ETF shares may only be redeemed directly with the ETF at NAV by Authorized Participants, in very large creation units. There can be no guarantee that an active trading
market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokeragecommissions and frequent trading may incur brokerage costs that detract significantly from investment returns.
The Adviser expects to invest at least 80% of the Fund's assets in Genomics Revolution Companies. However, certain of these companies do not currently derive a substantial portion of theircurrent revenues from genomic-focused businesses and there is no assurance that any company will do so in the future, which may adversely affect the ability of the Fund to achieve its investment
objective.
Index Descriptions: The S&P 500® Index is a widely recognized capitalization-weighted index that measures the performance of the large-capitalization sector of the U.S. stock market. TheMSCI World Index represents large and mid-cap equity performance across 23 developed markets countries. Returns shown for the MSCI World Index are net of foreign withholding taxes
applicable to U.S. investors. Securities in the ETF's portfolio will not match those in any index. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities
listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. The ETF
is benchmark agnostic and corresponding portfolios may have significant non-correlation to any index. Index returns are generally provided as an overall market indicator. You cannot invest
directly in an index. Although reinvestment of dividend and interest payments is assumed, no expenses are netted against an index's returns. Index performance information was furnished bysources deemed reliable and is believed to be accurate, however, no warranty or representation is made as to the accuracy thereof and the information is subject to correction.
Glossary: Active Share is a measure of the percentage of stock holdings in a manager's portfolio that differ from the benchmark index. Value Strategy: Traditional value investing is aninvestment strategy where stocks are selected that trade for less than their intrinsic values. Growth Strategy: Traditional growth investing is an investment strategy that focuses on stocks,
whose earnings are expected to grow at an above-average rate compared to its industry or the overall market. Correlation: The degree to which two strategies move in relation to each other.

Foreside Fund Services LLC, distributor.

NOT FDIC INSURED - NO BANK GUARANTEE - MAY LOSE VALUEARK Investment Management LLC
etfs@ark-invest.com | ark-funds.com | St. Petersburg, FL